Insider Trading March 24, 2026 07:17 PM

Amprius Technologies Director Sells $4.1M in Stock as Company Posts Strong Q4 Results

Director Sun Kang executed two transactions for 217,869 shares under a pre-arranged 10b5-1 plan; Amprius reported better-than-expected Q4 results and secured new customer wins and contract expansions

By Caleb Monroe AMPX

Sun Kang, a director at Amprius Technologies (NASDAQ: AMPX), sold 217,869 shares on March 23, 2026, in two transactions totaling about $4.1 million. The trades were completed under a Rule 10b5-1 plan adopted in August 2025. The company reported fourth-quarter 2025 results that beat expectations, recorded record quarterly revenue, added over 100 customers, and expanded key contracts, while shares have pulled back roughly 8% from their 52-week high.

Amprius Technologies Director Sells $4.1M in Stock as Company Posts Strong Q4 Results
AMPX

Key Points

  • Director Sun Kang sold 217,869 Amprius shares on March 23, 2026, in two transactions totaling about $4.1 million.
  • Amprius beat Q4 2025 expectations with EPS of -$0.01 and record quarterly revenue of $25.2 million; research firms raised price targets.
  • Company added over 100 new customers, secured a contract with Nokia Drone Networks, and expanded a Defense Innovation Unit contract from $10.5 million to $14.8 million - relevant to drone and defense sectors.

Director Sun Kang of Amprius Technologies (NASDAQ: AMPX) disposed of 217,869 shares of common stock on March 23, 2026, across two separate trades, for an aggregate value of approximately $4.1 million.

The sales were executed at weighted average prices spanning $17.89 to $19.36 per share. The first transaction accounted for 152,823 shares sold at an average price of $18.6863. The second transaction involved 65,046 shares sold at an average price of $19.0589. The reported volume and pricing place the combined proceeds near $4.1 million.

Following these transactions, Sun Kang continues to hold equity positions in Amprius both directly and indirectly. Indirect holdings include 177,858 shares held through the KANG & CECILLIA SUN FAMILY REVOCABLE TRUST. Direct holdings total 1,342,400 shares, which include 1,159,385 restricted stock units.

The reported trades were carried out under a pre-arranged Rule 10b5-1 trading plan that the director adopted on August 18, 2025.


These insider sales come as Amprius shares have experienced significant appreciation over the past year, delivering a 438% return year-over-year, though the stock has eased by about 8% in the past week from its 52-week high of $19.76.

On the operational and financial front, Amprius disclosed fourth-quarter 2025 results that outperformed analyst expectations. The company posted an earnings per share (EPS) of negative $0.01, which was better than the forecasted negative $0.05. Revenue for the quarter reached a record $25.2 million, topping the anticipated $24.5 million.

Market participants and research firms responded to the quarterly results with upward revisions to price targets. Craig-Hallum lifted its price target on Amprius from $17 to $21 and maintained a Buy rating. Cantor Fitzgerald raised its price target from $16 to $20, citing strong execution against growing demand.

Amprius also reported commercial and government wins in recent periods. The company said it added more than 100 new customers and secured a material contract with Nokia Drone Networks. In the government arena, Amprius expanded its Defense Innovation Unit contract from $10.5 million to $14.8 million.

Separately, Kensington Capital Acquisition Corp. VI completed its $230 million initial public offering on the New York Stock Exchange.


The combination of notable insider selling, a highly volatile share performance over the prior year, and recent operational progress sets a mixed backdrop for investors evaluating Amprius. The company has reported improved results and contract wins, while an ongoing negative EPS and short-term price pullback reflect continuing transition dynamics for the business.

Risks

  • Shares have pulled back roughly 8% in the past week from a 52-week high of $19.76, indicating short-term price volatility - relevant to public markets and investor sentiment.
  • The company reported a negative EPS of $0.01 for Q4 2025, highlighting ongoing losses despite revenue growth - relevant to equity valuation and capital markets.

More from Insider Trading

Edwards Lifesciences CEO Executes Multi-Million Dollar Share Sale via Pre-Set Trading Plan May 12, 2026 Covista CFO Executes $1.26 Million Stock Sale via Pre-Scheduled Trading Plan May 12, 2026 Covista Executive Executes Planned Share Sale Amidst Corporate Growth and Financial Restructuring May 12, 2026 Covista Executive Executes $1.22 Million Stock Sale Under Pre-Planned Trading Program May 12, 2026 Ameriprise Financial Director Executes Stock Sale Amid Strong Earnings Performance May 12, 2026